Robert W. Duggan, Co-Chief Executive Officer, 10% Owner at Summit Therapeutics Inc. (SMMT), bought 100,000 shares at $14.60 ($1.5M) on 2026-06-04, disclosed to the SEC on 2026-06-04.
CEO Robert W. Duggan purchased 100,000 shares for $1.46 million on June 4, signaling confidence in the company's pipeline. This move follows recent positive clinical data for ivonescimab and analyst upgrades.
The stock is currently trading at $16.12, up 6.68% over the last 90 days but still down 17.59% from its 1-year high of $30.98.
The stock carries significant risk due to a short interest of 22.11% and a recent Underperform rating from Bernstein on June 2.
Nothing distinguishes this filing.
| Filing → |
| SMMT | BUY | 2025-10-23 | $1000K | — | Filing → |
| PLSE | BUY | 2025-09-12 | $5.4M | — | Filing → |
| SMMT | BUY | 2025-09-11 | $11.9M | — | Filing → |